ArticleTranslational andrology and urology2025
Interpretable machine learning driven biomarker identification and validation for prostate cancer.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa), a common malignancy among men globally, requires the identification of biomarkers for early diagnosis and predicting progression. This study aimed to identify the key genes involved in the occurrence and development of PCa. Methods: Leveraging data from the Gene Expression Omnibus (GEO) database, this study integrated multi-chip datasets, conducting differential expression analysis and enrichment analysis to pinpoint PCa-related genes. Subsequently, machine learning models were constructed using least absolute shrinkage and selection operator (LASSO) regression, support vector machine (SVM), and random forest (RF) methods. The optimal model was selected for further study and the contribution of related genes was explained using SHapley Additive exPlanations (SHAP) analysis. Furthermore, gene set enrichment analysis (GSEA) and immune cell infiltration analysis were utilized to uncover the underlying molecular mechanisms. Results: In this study, 222 differentially expressed genes (DEGs) were identified and found to be enriched in functions and pathways potentially associated with PCa. Using multiple machine learning models, eight PCa-related core genes ( Conclusions: This study offered potential biomarkers and a theoretical basis for the diagnosis and treatment for PCa.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.